Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
about
T cell receptor signalling in the control of regulatory T cell differentiation and functionRegulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in TransplantationRegulatory T-cell therapy in transplantation: moving to the clinicThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseDifferential responses of human regulatory T cells (Treg) and effector T cells to rapamycinImmunoregulatory Effects of Everolimus on In Vitro Alloimmune ResponsesInduction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway.Lactic acid bacteria-specific induction of CD4+Foxp3+T cells ameliorates shrimp tropomyosin-induced allergic response in mice via suppression of mTOR signaling.Allogeneic T regulatory cell-mediated transplantation tolerance in adoptive therapy depends on dominant peripheral suppression and central tolerance.Immunoregulatory functions of mTOR inhibition.Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioningTGF-beta/atRA-induced Tregs express a selected set of microRNAs involved in the repression of transcripts related to Th17 differentiationIL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.Intracellular parasitism with Toxoplasma gondii stimulates mammalian-target-of-rapamycin-dependent host cell growth despite impaired signalling to S6K1 and 4E-BP1.Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantationInterleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapyFrequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipientsInfusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models.Pharmacotherapy for uveitis: current management and emerging therapy.Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection.Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study.Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer.CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation.Immunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry.Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway.A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model.mTOR signaling, Tregs and immune modulation.Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stabilityInhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantationCD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.Cellular size as a means of tracking mTOR activity and cell fate of CD4+ T cells upon antigen recognition
P2860
Q26749508-ADCDEC2D-1E54-40D0-A42F-6365DF0887F5Q26784460-EDD6EA6C-3F27-4649-8E5C-AB8152C472B4Q27025869-0F8D131B-0AC3-497D-B1C9-894A0BEBFBBAQ28076264-55A0BDA0-8B10-47F4-BDB9-C066724AD9ECQ28475626-6D348118-7E5B-4A66-87E9-253B758A938EQ28550145-BAA88098-2A5C-48A8-8B95-A352E07A6855Q30907499-85DE4C07-A268-4DFB-82B0-5F2114BCEE65Q33694810-B03922B6-8F6D-4DE0-8719-059364DFB46EQ33722667-E0A88B73-15B3-4DF5-AB24-E0FA937E58C4Q33761278-872A7589-6FB1-4BF4-BB95-0901C47910D4Q33796796-5F134731-2320-4B72-8785-23A2AA18F566Q33804010-0639F078-D221-44F5-B75C-3B2722402030Q33816022-904575EA-CAB1-4660-8620-2A4475C71C02Q33887452-0D8BE3B9-9464-4AEF-B60C-0F5CE1B8048DQ33894468-6FD67184-D5C9-4F39-9289-D37321D09604Q33898020-6453968F-1078-4E8D-B7C4-958DA7DB0B7DQ33917765-6BBDB1BA-FD15-4881-803A-EB76E2927078Q34044170-AFF63F29-E60C-4369-BABB-40944E7917B6Q34073891-DCA31AE2-B309-49FA-AFBC-0A89FB29DEC4Q34144161-D3519E8C-881B-4705-BC56-755B4B2EB8CEQ34170406-19C99DA1-CF5B-40BA-8CE8-E7E2CDF0EFE3Q34274075-25D89E3F-423D-4023-BCA4-77CB1EE49235Q34279929-3D3E319E-8983-43CE-8366-2B2654A5D719Q34400439-EC0031EF-6D70-4528-9D33-CE51FA90B83CQ34420372-9BA3A98F-F075-4BF7-A2A1-3C8E48301F01Q34437449-E53F063A-53AC-422C-9195-33FB15BC4858Q34449084-0AE02BCA-4DE2-4765-B88B-461B55603B7EQ34536661-E46DCBC0-9DB4-4A13-A331-CAE16AD751E5Q34551230-873A87AB-E147-414A-8531-0E8E61E56A0FQ34628368-84662041-F949-48DE-B4B8-F22A728999FCQ34635688-697A72C6-4175-4F1C-AFD2-1B8968283D77Q34681642-6715D09B-5DE8-4B7E-A35F-53C15DFD7CA4Q34732865-4C2D732A-B6CC-413E-90D0-0532F03366ABQ34919712-06A2D696-1B24-4100-B7ED-058B38EF20B6Q34979483-AE75E88B-5C79-4624-9D9B-CC0DBBDF827AQ35128301-CA3F38B2-14F9-4302-873C-48B50444A262Q35207094-E96CE5D7-0BC2-43AE-89C6-C0716819EFF5Q35231363-71137AA4-CB64-40DD-B2C4-1332821C3DD0Q35252405-06954E35-6A78-4E0E-8704-7F5A709C09F3Q35304382-1C59DCC7-F5AA-4956-909D-E35F692169F1
P2860
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Differential impact of mammali ...... with conventional CD4+ T cells
@ast
Differential impact of mammali ...... with conventional CD4+ T cells
@en
type
label
Differential impact of mammali ...... with conventional CD4+ T cells
@ast
Differential impact of mammali ...... with conventional CD4+ T cells
@en
prefLabel
Differential impact of mammali ...... with conventional CD4+ T cells
@ast
Differential impact of mammali ...... with conventional CD4+ T cells
@en
P2093
P2860
P1433
P1476
Differential impact of mammali ...... with conventional CD4+ T cells
@en
P2093
Andreas Beilhack
Dennis B Leveson-Gower
Elizabeth A Zambricki
Jing-Zhou Hou
Neeraja Kambham
Robert S Negrin
Robert Zeiser
P2860
P304
P356
10.1182/BLOOD-2007-06-094482
P407
P577
2007-10-29T00:00:00Z